Your support is leading to results!

Roche Laboratories, teamed with other researchers, just published results describing a compound that reverses impaired brain cell signaling in a mouse model with Down syndrome.
The data demonstrated major cognitive and behavioral improvements in the mouse
model.

In 2011, Roche initiated a human clinical trial testing compound, RD 1662,
in persons with Down syndrome. This is a Phase I trial testing drug safety
and tolerability. Roche expects to complete this study this year. The compound
had already been tested in healthy volunteers and was shown to be well
tolerated. A second, non-drug study to evaluate cognition and adaptive behavior
in adolescents and young adults with Down syndrome is also underway.

Your contributions to Down Syndrome research helped fund the field of Down
syndrome cognitive research and the discovery of other potential drug
therapies.

Down Syndrome Development Trust will continue to use your generous donations to ensure greater life opportunities for persons with Down syndrome.